CAMBRIDGE, MA: The Novartis Institutes for BioMedical Research (NIBR), the Swiss drug giant's global research organization, has named Feinstein Kean Healthcare (FKH) its first-ever agency of record.
Marcia Kean, CEO of FKH, said it's the shared expertise of the agency and institute in both pharmaceuticals and biotechnology that made them both a good fit.
"We are very much at that intersection between big pharma and biotech. NIBR is at that same intersection," said Kean.
NIBR, which was created to help advance pharmaceutical discoveries, has its headquarters in Cambridge, but has seven sites around the globe. FKH, also Cambridge-based, will handle PR for all of the locations.
Kean said PR efforts would be targeted at the biotech community, academic medical centers and policy makers.
"You can't be siloed in who you talk to anymore," said Kean. "Unfortunately, the pharma industry has done a bad job of communicating with its constituents. This is an opportunity to change some of those perceptions."